Research and Markets: Global Multiple Myeloma Drug Market & Pipeline Insight 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/t4wv4l/global_multiple) has announced the addition of the "Global Multiple Myeloma Drug Market & Pipeline Insight 2015" report to their offering.

Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years.

Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression.

"Global Multiple Myeloma Drug Market & Pipeline Insight 2015" Report Highlight:

- Global Multiple Myeloma Drug Market Analysis

- Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase

- Marketed Multiple Myeloma Drugs Clinical Insight

- Mechanism of Multiple Myeloma Drug

- Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs

- Majority Multiple Myeloma Drugs in Phase-II Trials: 40

- Marketed Multiple Myeloma Drugs: 9

Competitive Landscape

- AbbVie

- Altor BioScience

- Astellas Pharma

- Astex Pharmaceuticals

- Benovus Bio

- Biogen Idec

- Bristol-Myers Squibb

- Celegen Pharmaceuticals

- Cleave Biosciences

- Genmab

- Novartis

- Onyx Pharmaceuticals

- Pfizer

- Millennium Pharmaceuticals

- Vaxil Biotherapeutics

For more information visit http://www.researchandmarkets.com/research/t4wv4l/global_multiple

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices